Pandemic fears force Chinese biotech to postpone Hong Kong IPO meetings — Bloomberg
At the same time the coronavirus outbreak originating from Wuhan is boosting shares prices of a raft of (mostly overseas) drugmakers, it appears to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
